Clovis Oncology, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2020-12-21: Form 8-K; Period of report 2020-12-21; Description 8.01 Other Events; Details 8.01.
- 2020-11-27: Form 8-K; Period of report 2020-11-27; Description 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events; Details 2.03.
- 2020-11-17: Form 8-K; Period of report 2020-11-17; Description 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; Details 2.03.
- 2020-11-05: Form 8-K; Period of report 2020-11-04; Description 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2020-12-21 | 8-K | 2020-12-21 | 8.01 Other Events | 8.01 On December 21, 2020, Clovis Oncology, Inc. (the “Company”) announced topline data from the randomized Phase 3 ARIEL4 study of Rubraca, which met its primary endpoint of improved investigator-assessed progression-free survival (InvPFS) compared to chemotherapy in relapsed ovarian cancer patients with a tumor mutation of BRCA who have received two or more prior lines of chemotherapy. | d47125d8k.htm |
| 2020-11-27 | 8-K | 2020-11-27 | 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 2.03 On November 27, 2020, Clovis Oncology, Inc. (the “Company”) completed the sale of $7,500,000 aggregate principal amount of its 4.50% Convertible Senior Notes due 2024 (the “Additional Notes”) at a purchase price of $1,000 per $1,000 principal amount of Additional Notes. 3.02 The information with respect to the Additional Notes and the Indenture set forth in Item 2.03 of this Current Report on Form 8-K is incorporated herein by reference. 8.01 On November 24, 2020, the Company issued a press release announcing the exercise by the Holder of its option to purchase the Additional Notes. | d97249d8k.htm |
| 2020-11-17 | 8-K | 2020-11-17 | 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 2.03 On November 17, 2020, Clovis Oncology, Inc. (the “Company”) consummated its previously announced debt exchange transaction and offering of convertible senior notes pursuant to that certain Exchange and Purchase Agreement (the “Agreement”), dated as of November 4, 2020, by and between the Company and a holder (the “Holder”) of its currently outstanding 4.50% Convertible Senior Notes due 2024 (the “Existing 2024 Notes”). 3.02 In addition, pursuant to the Agreement, the Company issued to the Holder 15,112,848 shares of its common stock (the “Exchanged Shares”) in exchange for $64,842,000 aggregate principal amount of Existing 2024 Notes held by the Holder. | d88033d8k.htm |
| 2020-11-05 | 8-K | 2020-11-04 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 On November 5, 2020, Clovis Oncology, Inc. (the “Company”) announced that it has entered into a privately negotiated exchange and purchase agreement (the “Exchange and Purchase Agreement”) with a holder of its currently outstanding 4.50% Convertible Senior Notes due 2024 (the “Existing 2024 Notes”). 2.03 The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. 3.02 The New 2024 Notes will be offered pursuant to the exemption provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). 8.01 On November 5, 2020, the Company issued a press release announcing the transactions contemplated by the Exchange and Purchase Agreements. | d11902d8k.htm |
| 2020-11-05 | 8-K | 2020-11-05 | 2.02 Results of Operations and Financial Condition | 2.02 On November 5, 2020, Clovis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2020. | d30873d8k.htm |
| 2020-08-06 | 8-K | 2020-08-06 | 2.02 Results of Operations and Financial Condition | 2.02 On August 6, 2020, Clovis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2020. | d29090d8k.htm |
| 2020-06-04 | 8-K | 2020-06-04 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 On June 4, 2020, the stockholders of Clovis Oncology, Inc. (the “Company”) approved and adopted the Company’s 2020 Stock Incentive Plan (the “2020 Plan”) at the Company’s Annual Meeting of Stockholders. 5.07 The Annual Meeting of Stockholders of the Company was held on June 4, 2020. | d937814d8k.htm |
| 2020-05-21 | 8-K | 2020-05-18 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure; 8.01 Other Events | 1.01 On May 18, 2020, Clovis Oncology, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC and BofA Securities, Inc., as underwriters (the “Underwriters”), relating to the issuance and sale of 11,090,000 shares of common stock, par value $0.001 per share, of the Company (the “Shares”). 7.01 Based on the Company’s currently anticipated revenues, spending, available financing sources and existing cash, cash equivalents and available-for-sale securities, the Company believes that following the completion of the offering of the Shares described under Item 1.01 of this Current Report (even assuming no exercise by the underwriters of their option to purchase additional shares of common stock) the Company will have sufficient cash, cash equivalents and available-for-sale securities to fund its operating plan into early 2022. 8.01 On May 18, 2020, the Company issued a press release announcing the commencement of the offering. | d934830d8k.htm |
| 2020-05-05 | 8-K | 2020-05-05 | 2.02 Results of Operations and Financial Condition | 2.02 On May 5, 2020, Clovis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2020. | d915317d8k.htm |
| 2020-04-16 | 8-K | 2020-04-14 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 On April 14, 2020, the Board of Directors of Clovis Oncology, Inc. (“the Company”) amended the Company’s Amended and Restated Bylaws (the “Bylaws Amendment”) to adopt a new Section 7.4: Exclusive Forum, a provision designating the federal district courts of the United States as the exclusive jurisdiction for any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. | d919895d8k.htm |
| 2020-04-14 | 8-K | 2020-04-14 | 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 2.03 The information with respect to the Additional 2024 Notes set forth in Item 3.02 of this Current Report on Form 8-K is incorporated herein by reference. 3.02 On April 14, 2020, Clovis Oncology, Inc. (the “Company”) announced that it has entered into a privately negotiated exchange agreement with a holder (“Holder”) of its outstanding 2.50% Convertible Senior Notes due 2021 (the “2021 Notes”), pursuant to which the Company has agreed to issue to such Holder of the 2021 Notes approximately $36.05 million in aggregate principal amount (the “Additional 2024 Notes”) of its currently outstanding series of 4.50% Convertible Senior Notes due 2024 (the “2024 Notes”) in exchange for approximately $32.77 million in aggregate principal of 2021 Notes held by such Holder (the “Exchange Transaction”). 8.01 On April 14, 2020, the Company issued a press release announcing the Exchange Transaction. | d898640d8k.htm |
| 2020-02-24 | 8-K | 2020-02-24 | 2.02 Results of Operations and Financial Condition | 2.02 On February 24, 2020, Clovis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2019. | d890302d8k.htm |
| 2020-01-08 | 8-K | 2020-01-07 | 8.01 Other Events | 8.01 On January 8, 2020, Clovis Oncology, Inc. (the “Company”) consummated its previously announced registered direct offering (the “Share Offering”) of an aggregate of 17,777,679 shares (the “Shares”) of its common stock at a price of $9.25 per share to a limited number of holders (the “Holders”) of its 4.50% Convertible Senior Notes due 2024 (the “2024 Notes”). | d864205d8k.htm |
| 2020-01-07 | 8-K | 2020-01-07 | 2.02 Results of Operations and Financial Condition | 2.02 On January 7, 2020, Clovis Oncology, Inc. (the “Company”) issued a press release announcing certain unaudited preliminary financial results for the quarter and fiscal year ended December 31, 2019. | d856487d8k.htm |